Trigemina Presents At American Pain Society 32nd Annual Scientific Meeting
MORAGA, Calif., May 9, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced that David C. Yeomans, Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at Stanford University School of Medicine, gave a presentation at the American Pain Society (APS) 32 nd Annual Scientific Meeting on May 8 th, 2013, in New Orleans, Louisiana.
Dr. Yeomans was selected by the APS to present data on Trigemina's lead product candidate, TI-001, an intranasal oxytocin pain therapy, during the Clinical and Basic Science Data Blitz event on Wednesday, May 8 th, from 6 PM to 8 PM ET. The blitz was composed of innovative and compelling presentation of new research, with presenters having five minutes to present and an additional five minutes to answer questions from the audience.
"The need to share and discuss new research in pain has become increasingly important, especially when considering the impact that prescription drug abuse has had on our country in recent years," said Dr. Yeomans. "The APS Data Blitz provides researchers and physicians with valuable information on emerging therapies, like TI-001, which may one day provide a safe, non-addictive and effective solution to people suffering from chronic pain."
TI-001 is currently being evaluated in a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study, titled TRIG-05, for efficacy, tolerability and safety in patients with chronic migraine. Promising preclinical and human pilot study results suggests TI-001 could be a safe, non-narcotic form of therapy for the effective relief of chronic migraine, a debilitating condition with few treatment options.About TrigeminaTrigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain. For additional information, please visit www.trigemina.com Contact: The Ruth Group Aaron Estrada (media) firstname.lastname@example.org (646) 536-7028 Trigemina Charles Yeomans email@example.com(925) 377-0664 SOURCE Trigemina, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV